bluebird bio, Inc. (BLUE) 


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of bluebird bio, Inc ("bluebird" or "the Company") (NASDAQ: BLUE). The investigation concerns whether bluebird and certain of its officers and/or directors have violated federal securities laws.


On November 4, 2020, bluebird disclosed that the Company will no longer be applying for U.S. Food and Drug Administration (“FDA”) approval of its bb1111 product as a treatment for sickle cell disease in the second half of 2021 as expected.  Instead, citing “feedback” from the FDA, “alongside COVID-19 related shifts and contract manufacturing organization COVID-19 impacts, bluebird is adjusting its submission timing to late 2022.”  On this news, bluebird’s stock price fell $2.94 per share or 6.02%, to close at $45.89 per share on November 6, 2020.


If you are aware of any facts relating to this investigation, or purchased bluebird shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.